News

Recordati Rare Diseases announces today that Lancet Diabetes & Endocrinology has published positive results from the Phase III LINC-3 pivotal study of Isturisa®, recently approved for the treatment

Wie Recordati Rare Diseases heute bekannt gibt, hat das Journal Lancet Diabetes & Endocrinology positive Ergebnisse der Phase-III-Zulassungsstudie LINC-3 für Isturisa^® veröffentlicht, das kürzlich

Mit dem Cortisolsynthese-Hemmer Osilodrostat (Isturisa®) steht seit 15. Juli 2020 in Deutschland eine vielversprechende neue Therapieoption zur medikamentösen Behandlung von erwachsenen Patienten

Cortisol synthesis inhibitor osilodrostat (Isturisa®) is now available in Germany as of July 15, 2020, as a promising new therapy option for medical treatment of adult patients with endogenous

Recordati Rare Diseases meldet heute positive Ergebnisse der großen Phase-III-Studie LINC-4 zur Prüfung von Isturisa^® (Osilodrostat) zur Behandlung von Patienten mit Morbus Cushing, die für eine

Recordati Rare Diseases today announces positive results from the large Phase III LINC-4 study of Isturisa® (osilodrostat) for the treatment of patients with Cushing’s disease for whom pituitary

Recordati Rare Diseases meldete heute die Ausbietung von Isturisa® (Osilodrostat). Gemäß einer von der französischen Nationalen Arzneimittelagentur (ANSM) erteilten vorläufigen

Recordati Rare Diseases announced today the commercial availability of Isturisa® (osilodrostat). Over 50 patients with Cushing’s syndrome have already been initiated on Isturisa® under temporary

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral

Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral